DDInter38 DDInter1676
Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Aldesleukin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epirubicin
Aldesleukin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anakinra
Aldesleukin {u} may lead to a major life threatening interaction when taken with {v} Rotavirus vaccine
Aldesleukin {u} may lead to a major life threatening interaction when taken with {v} Interferon alfa-n1
Aldesleukin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Anakinra
Aldesleukin may lead to a major life threatening interaction when taken with Rotavirus vaccine
Aldesleukin may lead to a major life threatening interaction when taken with Interferon alfa-n1